Abstract: SA-PO0569
Cardiovascular Comorbidities of ADPKD in the US Military Health System (MHS)
Session Information
- Cystic Kidney Diseases: Clinical Research
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases
Authors
- Nguyen, Julia, Walter Reed National Military Medical Center, Bethesda, Maryland, United States
- Nee, Robert, Walter Reed National Military Medical Center, Bethesda, Maryland, United States
- Marneweck, Hava, Henry M Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, Maryland, United States
- Banaag, Amanda, Henry M Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, Maryland, United States
- Koehlmoos, Tracey L., Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
- Oliver, James D., Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
Background
PKD has known associations with cardiovascular conditions, however, quantitative comparisons to the general population and to other forms of chronic kidney disease (CKD) are not well-established. Here we report on prevalence and odds ratios for several major comorbidities in a large PKD population from the MHS, a global US Department of Defense healthcare network.
Methods
For the 2022 enrollment of 5,028,667 beneficiaries (all ages), we used diagnosis codes and/or labs to identify 3,382 (0.07%) with PKD (PKD+), 264,883 (5.3%) with non-PKD CKD (CKD+/PKD–), and 4,760,402 (94.7%) without CKD (CKD–). The outcomes were prevalence of diabetes (DM), hypertension (HTN), hyperlipidemia (HLD), cerebrovascular disease (CBVD), atherosclerotic/ischemic heart disease (ASHD/IHD), heart failure (HF) and valvular heart disease (VHD). Adjusted odds ratios (aOR) for each condition were calculated by multivariable logistic regression, accounting for demographics and the presence of other comorbidities.
Results
The median age (IQR) of each cohort was 47 (32–60) for PKD+, 55 (40–64) for CKD+/PKD–, and 27 (16–42) for CKD–. For each condition crude prevalence was the lowest in CKD– and, with the exceptions of HTN and CBVD, was higher in CKD+/PKD– vs PKD+ (Table). For PKD+ vs CKD–, aOR were > 1 for all conditions (p<.05) except for DM, which was not significant. For PKD+ vs CKD+/PKD–, aOR were > 1 for HTN and CBVD (p<.05); < 1 for DM and HLD (p<.05); and not significant for ASHD/IHD, HF, and VHD.
Conclusion
In the MHS, PKD is significantly associated with increased odds of cardiovascular comorbidities versus the non-CKD population, with the notable exception of DM. Compared to other forms of CKD, PKD is associated with higher odds of HTN and CBVD but lower odds of DM and HLD. Further investigation into demographic associations and other risk factors may be indicated.
The views expressed are those of the authors and do not reflect the official position of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense, or the US Government.
Funding
- Other U.S. Government Support